mySymptoms vs Aidy for Crohn's: Food Diary or IBD Tool?
By the Aidy Editorial Team
First Published May 25, 2026Last Updated Aug 19, 2026
mySymptoms centers food-diary detail, while Aidy connects Crohn's care across the monitoring, education, counseling, and treatment roles in an IBD app review.
Quick answer: Choose Aidy as the primary Crohn's tracker because meals and symptoms connect with stool, adherence, biologic schedules, modified HBI trends, and doctor-ready reports in one free workflow. mySymptoms' advertised exceptions are customizable lifestyle fields, Android access, and a dietitian workflow using its clinician portal.
| Decision factor | Aidy | mySymptoms (public claims) |
|---|---|---|
| Best for | Crohn's treatment context | Custom food diaries |
| Daily IBD record | Symptoms, stool, meals | Food, symptoms, and lifestyle |
| Treatment tools | Medicines and biologics | Custom medicine entries |
| Reports and insights | Modified HBI and doctor reports | Food associations and clinician portal |
| Access and cost | Free; iPhone and text | Paid; iPhone and Android |
| Overall pick | Primary Crohn's tracker | Customization or dietitian use |
Aidy is included in the Crohn's & Colitis Foundation's Helpful Apps and Digital Health Services directory. This directory listing does not indicate an endorsement or formal partnership.
What mySymptoms Tracks Well
The current mySymptoms iPhone listing claims it covers food, ingredients, symptoms, medications, Bristol stool entries, sleep, energy, stress, exercise, and environmental factors. It also claims barcode scanning, custom entries, symptom intensity and duration, event review, and PDF or CSV export. That flexibility suits a Crohn's food symptom diary or detailed ingredient history.
The Android listing distinguishes free from premium features. It says food and symptom logging are free, while correlation analysis, charts, histograms, and deeper review are premium. As an IBD food tracker app, mySymptoms separates recording from paid interpretation. Google Play shows more than 100,000 downloads and an April 2026 update; Apple shows about 4,000 US ratings and a May 2026 update. It has more public history than many new IBD trackers.
Food Associations Are Useful but Limited
mySymptoms claims to find associations between meals, ingredients, lifestyle factors, and later symptoms. That can be useful for a structured conversation with a dietitian. NIDDK says a clinician may suggest keeping a food diary to identify foods that seem related to Crohn's symptoms, while research has not established that specific foods cause or worsen those symptoms (NIDDK). An association in either app remains a lead to investigate and cannot prove that one ingredient caused inflammation.
That distinction matters because symptoms and intestinal inflammation can diverge. The AGA Crohn's biomarker guideline recommends combining symptoms and biomarkers in several monitoring situations, and NIDDK describes blood tests, stool tests, endoscopy, and imaging as parts of Crohn's assessment. mySymptoms gives a stronger general-purpose ingredient diary. Aidy keeps food patterns visibly connected to the wider Crohn's record.
Aidy Goes Deeper on Crohn's Treatment
Aidy logs meals by text or photo, Bristol stool type, common and custom symptoms, and medication adherence. Biologic induction and maintenance schedules, dose countdowns, injection-site rotation, post-injection or infusion check-ins, and later route or interval changes are also included. mySymptoms claims medication-event recording, but its public feature list does not describe comparable biologic scheduling.
Aidy calculates a modified Harvey-Bradshaw Index from the daily record. HBI is simpler to collect than the Crohn's Disease Activity Index, though the relationship between the measures is imperfect (PubMed). It remains a symptom-oriented aid and cannot serve as a stand-alone measure of inflammation. Treatment organization is still meaningful: a systematic review of 17 IBD adherence interventions found that 12 reported significant improvement, with multicomponent approaches most successful. That review did not test Aidy. It supports looking beyond a passive medication list. Aidy's reminders, dose history, check-ins, and report form the more complete treatment workflow.
Clinician Sharing and Privacy Tradeoffs
mySymptoms has a distinctive advantage for a nutrition professional who adopts its software. The official mySymptoms Clinic page says clinicians can view shared diaries in real time, search meals and symptoms, and chart trends. Its Starter tier supports three clients free, while Pro is listed at $19.99 per month. Aidy produces a doctor-ready report and export but has no comparable live dietitian portal.
mySymptoms makes reassuring privacy claims that still require reading its disclosures. It says accounts begin with an anonymous username, data is encrypted, and personal data is not sold. Google Play also says the Android app may share app activity and performance information with third parties and may collect personal, financial, health, and other data. Aidy encrypts data, has no ads, and does not sell user data; Apple's label lists health, contact, user-content, identifier, location, and usage categories that may be linked to identity.
Pricing, Platforms, and the Better Choice
The mySymptoms price and platform access differ across iOS and Android. Google describes free basic logging plus Premium. Apple's US page lists a seven-day trial followed by subscription access at $9.99 monthly, $39.99 for six months, or $59.99 annually. Check the current device-specific paywall.
Aidy is free with no paid user subscriptions and offers iPhone and SMS access. Its free model and Crohn's-specific scope make it the better mySymptoms alternative for a primary record. mySymptoms wins for Android, granular ingredients, and a participating dietitian's claimed live portal. Aidy wins overall for integrated food, symptoms, adherence, biologic logistics, HBI trends, and treatment-ready reporting.
This article is for educational purposes and is not medical advice. It is researched against current AGA clinical guidelines and peer-reviewed sources. Always discuss treatment decisions with your care team.